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Feature Fusion of Raman Chemical Imaging and Digital Histopathology using Machine Learning for Prostate
Cancer Detection
Trevor Doherty,a∗ Susan McKeever,a Nebras Al-Attar,b,g Tiarnán Murphy,b Claudia Aura,c
Arman Rahman,c Amanda O’Neill,d Stephen P Finn,e Elaine Kay, f William M. Gallagher,c
R. William G. Watson,d Aoife Gowenc‡ & Patrick Jackmana‡

The diagnosis of prostate cancer is challenging due to the heterogeneity of its presentations, leading to
the over diagnosis and treatment of non-clinically important disease. Accurate diagnosis can directly
benefit a patient’s quality of life and prognosis. Towards addressing this issue, we present a learning
model for the automatic identification of prostate cancer. While many prostate cancer studies have
adopted Raman spectroscopy approaches, none have utilised the combination of Raman Chemical
Imaging (RCI) and other imaging modalities. This study uses multimodal images formed from stained
Digital Histopathology (DP) and unstained RCI. The approach was developed and tested on a set of
178 clinical samples from 32 patients, containing a range of non-cancerous, Gleason grade 3 (G3) and
grade 4 (G4) tissue microarray samples. For each histological sample, there is a pathologist labelled
DP - RCI image pair. The hypothesis tested was whether multimodal image models can outperform
single modality baseline models in terms of diagnostic accuracy. Binary non-cancer/cancer models
and the more challenging G3/G4 differentiation were investigated. Regarding G3/G4 classification,
the multimodal approach achieved a sensitivity of 73.8% and specificity of 88.1% while the baseline
DP model showed a sensitivity and specificity of 54.1% and 84.7% respectively. The multimodal
approach demonstrated a statistically significant 12.7% AUC advantage over the baseline with a
value of 85.8% compared to 73.1%, also outperforming models based solely on RCI and median
Raman spectra. Feature fusion of DP and RCI does not improve the more trivial task of tumour
identification but does deliver an observed advantage in G3/G4 discrimination. Building on these
promising findings, future work could include the acquisition of larger datasets for enhanced model
generalization.

1

Introduction

Cancer is a primary cause of morbidity and mortality worldwide
with prostate cancer having the second highest incidence of can-
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cer among men. 1 It is estimated that prostate cancer will account for 33,330 deaths and 191,930 new cases in the U.S. in
2020. 2 Manual histologic assessment of prostate tissue biopsies
by a pathologist constitutes the definitive diagnosis of prostate
cancer. 3 Pathologists utilize advanced imaging techniques and
biomarker discovery through the use of Haematoxylin and Eosin
(H&E) to visually analyze the morphological features within a
prostate tissue sample and use the Gleason grading system 4,5 to
identify nonmalignant, benign hypertrophic and malignant prostatic tissues. Limitations of this staining process including reactivity to staining agents from different manufacturers, tissues’
thickness, stain concentration, batch effects, room temperature
during preparation and alteration of the applied method lead to
staining variation across use cases. 6–8 This, in addition to factors
such as the extent of a pathologist’s skill and training in Gleason
grading, weariness due to the laborious assessment procedure
and subjectivity introduce error into the pathologist report and
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have led to high rates of interobserver variability. 9–11 Computeraided diagnosis can be employed to support pathologists, increase
efficiency and accuracy and ultimately benefit the patient. 12
Fundamental differences in the molecular expression of a range
of diseases including some cancers tend to present themselves as
changes in tissue architecture and nuclear morphology. As a result, there has been significant interest in the use of digital pathology to develop algorithms and feature extraction methods for the
automatic classification of tissue types, the grading of disease and
prediction of disease prognosis. 13 In addition to digital pathology,
spectroscopic methods are highly suitable for the in situ observation of molecular changes, allowing characterization of complex
biological systems. 14 By interrogating chemical content, Raman
scattering can produce a detailed fingerprint of a material. 15 Raman spectroscopy as the most dominant spectral technique has
shown details of molecular information with the ability to provide
qualitative and quantitative biochemical signatures in addition to
sample morphology. 16 Furthermore, Raman spectroscopy can simultaneously identify and detect a variety of molecular structures
such as proteins, DNA, RNA, and lipids in a single acquisition. 17
Chemically complex milieux of biological samples revealed by Raman spectroscopy allow investigation of functional groups, bonding types and molecular conformations and have led to markers
for cancer detection. 18 Consequently, Raman spectroscopy has
been applied to a range of cancer modalities such as colon, 19,20
skin, 21 breast, 22 lung, 23 cervix 24 and prostate 25,26 among others.
Prostate adenocarcinoma has shown to be difficult to accurately characterize, partially due to histological heterogeneity of
samples. This characteristic heterogeneity is more suited to an
approach based on image analysis as opposed to ’point’ spectroscopy. 27 Kast et. al suggested that an opportunity exists to
combine the power of Raman spectroscopy with imaging technologies as this would allow correlation of sample morphology
with molecular information. 28 Raman chemical imaging (RCI)
is a novel emerging approach that utilises conventional Raman
spectroscopy with a spatial mapping process that results in a detailed chemical map of the sample containing biochemical information that is imperceptible by conventional methods. Utilising
RCI, Samiei et al. found that it showed promise as a technique
in the identification of patients who were at risk of post-radical
prostatectomy progression, indicating distinctive chemical differences in biochemical failure Gleason 7 patients, 29 while Tollefson
et al. observed distinctive chemical differences between prostate
tissue for patients that progressed to metastatic disease and those
that didn’t. 27
While many prostate cancer studies in the current literature
utilise Raman spectroscopy-based approaches, 30–34 none have
explored the combination of RCI with other imaging modalities.
RCI applied to the identification of cancer biomarkers in prostate
tissue could lead to improvements in current identification processes by complementing traditional staining methods. Image fusion methods incorporating multi-sensor and multi-source data
offer a wider diversity of potential features for medical analysis
applications. 35,36 Adopting a multimodal microscopy approach
for the automated analysis of prostate cancer, Kwak et al. com-
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bined imaging data from Fourier transform infra-red and optical
microscopy and achieved better accuracy on the fusion of these
data sources than a single data source alone. 37 The combination of coherent anti-Stokes Raman scattering, two-photon excited fluorescence and second harmonic generation microscopy
showed promise in differentiation of head and neck cancers and
non-cancerous epithelium 38 while Patil et al. demonstrated that
the integration of Raman spectroscopy with Optical Coherence
Tomography (OCT) enhanced the detection of ex-vivo breast cancer when compared with either approach alone. 39 Investigating
colonic adenocarcinoma, Ashok et al. used Raman spectroscopy
and OCT which individually yielded sensitivities of 89% and 77%
respectively and specificities of 78% and 74% respectively. Both
sensitivity and specificity improved to 94% for the combined
imaging model. 40 Yuan et al. devised a predictor for breast cancer survival that combined both image and gene expression analyses that significantly outperformed models that used only a single
data source. 41 This study proposes the development of a multimodal machine learning model that integrates features from both
digital histopathology and RCI.
Many approaches extract quantitative morphological information from histopathology sample images. For the automatic Gleason grading of prostate cancer, Nguyen et al. extracted morphological and phase based features relating to glands and surrounding stroma to predict disease pathology. 42 Lee et al. utilised domain inspired features for the prediction of biochemical recurrence of prostate cancer 43 while, in a study on male breast cancer, Veta et al. found mean nuclear area to be a significant prognostic indicator. 44 Doyle et al. utilized architectural and textural
features to achieve an accuracy of 76.9% for the classification of
Gleason grade 3 and 4 histological tissue patches. 45 Novel explicit
shape descriptors have been used to differentiate between intermediate Gleason grade (grades 3 and 4) prostate glands using
histopathology images with an accuracy of 89% and AUC of 0.78
being reported. 46 Linder et al. utilised local binary patterns for
the segmentation of tumour stromal and epithelial regions using
bright field microscopy for colorectal cancer. 47 Jafari-Khouzani
and Soltanian-Zadeh utilized energy and entropy features of multiwavelet coefficients in order to classify prostate cancer Gleason
scores from optical microscopy images. 48 Sanghavi et al. adopted
Speeded Up Robust Features (SURF) and Scale Invariant Feature
Transform (SIFT) with Bag of Visual Words (BoVW) to identify
prostate cancer grades from histopathology images. 49
SIFT is a feature detection algorithm from the field of computer
vision which locates and describes distinctive invariant image features. 50 Clustering of feature vectors yields cluster centroids that
characterize visual words. Pretrained dictionaries can be used to
map descriptors within new images to the closest visual word.
An image can then be represented as a histogram of its component visual words, generating an input vector for a classification
algorithm. Deep learning and transfer learning have shown efficacy when applied to the analysis and classification of cancer and
other diseases. 51–58 A drawback of deep learning is that it requires large amounts of training data, which is not commonly the
case in the medical domain. Several studies have demonstrated
promise on prostate cancer detection using deep learning, how-

ever these studies have utilised relatively large patient cohorts
and image sets. Ishioka, 59 Arvaniti, 60 Litjens 61 and Song’s 62
studies contained 335, 886, 225 and 195 patients respectively.
Where large numbers of samples are not available and deep learning is not applicable, well established computer vision techniques
such as SIFT come into play. 63 Wang et al. chose the SIFT image
feature with bag-of-word model as the non-deep learning representative method in their comparison of deep-learning versus
non-deep learning for the classification of prostate cancer using
MRI images. 64 SIFT with BoVW was one of the main representative methods for computer aided diagnosis algorithms before the
era of deep learning as can be seen in the results of ImageNet
2012. 65 It is, therefore, still a valuable approach when dataset
size precludes the use of deep learning technology and is used in
this study.
The current study which developed models that classify
prostate tissue samples goes beyond existing studies by integrating features of both Raman chemical and histopathology images.
The main research question was whether models trained on multimodal images can classify prostate cancer tissue samples more
effectively than a range of single modality baseline models utilizing digital histopathology imaging, Raman chemical imaging
or median Raman spectra. Specifically, the study aimed to investigate these approaches through the binary classifications of
cancer/non-cancer and Gleason grade 3/ grade 4 tissue samples
with the latter case relating to the much more challenging and
clinically relevant assessment of cancer severity. This research
constitutes an initial evaluation of the approach with more data
being necessary for a generalizable model.

2

Materials and Methods

2.1

Histopathology sample preparation Raman Mapping

A formalin fixed paraffin embedded prostate tissue microarray
(TMA) of 32 patients was obtained from the Irish Prostate Cancer Research Consortium (PCRC) with ethical approval and patient written consent. This TMA set consists of three TMA blocks
comprising 178 cores. The TMA sections were cut and placed
on a standard microscopic slide. The optimal tissue thickness
was investigated through employing various block cut thicknesses
(4,8,10, and 16 µm). 66 A 10 µm TMA thickness was the optimal
choice for Raman imaging as it provided spectra that were relatively free of interference from the substrate. Additionally, this
thickness allowed a sufficient layer of tissue to include features
such as epithelial cells, stroma, fibroblast, and red blood cells.
Samples were then baked in the oven at 60◦ C for one hour
and allowed to dry. A de-paraffinization protocol was introduced
to effectively remove paraffin from the tissue sections, described
as follows: samples were consecutively dewaxed in three baths
of xylene for 6 minutes each followed by three baths of graded
ethanol (100%, 90%, and 80%), also for 6 minutes each. The
samples were rehydrated by immersing them in deionized water
for 6 minutes. The rehydrated tissues were then kept in deionized
water in petri dishes in advance of Raman imaging tissue spectral
acquisition. Rehydrated samples were imaged on standard glass
slides under water immersion. After Raman imaging tissue sam-

ples were manually stained with Haematoxylin-Eosin.
Raman imaging spectroscopy was performed using a Renishaw inVia Micro-Raman confocal spectroscopy system (Renishaw, Wotton-under-Edge, Gloucestershire, UK) fitted with a
532nm and 785nm solid-state diode laser. The 532nm laser
was selected to perform Raman Imaging. Raman spectra were
recorded using water immersion x63 objective and a grating (600
line/mm) with a 1 second acquisition time. Before spectral data
was gathered a brightfield montage of the entire slide was collected in order to assist in targeting the TMA cores and minimise
the amount of data collected from empty sections of the slide.
Experiments could then be queued to run consecutively. Multiple
single point scans were used to perform map image acquisition.
A rectangular grid was created to sample the core surface using
WiRE software version 4.1. The dimensions of the grid step size
were 33µm in the x direction and 33µm in the y direction. The total mapped area varied according to the slight variability in TMA
core size, ranging from 19x31 pixels to 48x37 pixels.

2.2

TMA digitization

Hematoxylin solution modified acc. to Gill II and Eosin Y-solution
0.5% aqueous were purchased from Sigma-Aldrich to perform
staining on the PCRC Cohort after completion of Raman acquisition. H&E staining was performed in one batch using routine clinical protocols. 67 H&E slides were cover-slipping and digitized at
20x magnification using a whole slide scanner (Aperio ScanScope
CS, Leica Biosystems, Buffalo Grove, IL, United States). For crossvalidation of Gleason score (GS), the digitized H&E TMA images
were investigated at the core-level by histopathology. These images were annotated corresponding to the TMA map core description using Oncotopix 68 (from Visiopharm) Version 2019.07
platform. Hence, the TMA map was loaded to the Visiopharm
platform to obtain TIFF format images for individual cores which
correspond to patient ID. This allows the pathologist to validate
the H&E staining, GS crosscheck, and annotate the tumours for
individual cores. Meantime, the cores containing artifacts of the
histological processing (e.g., tissue folds, debris), were demarcated using the same tools. These cores were ultimately excluded
from Raman Imaging data. Digitized cores and their annotations
were stored and managed.

2.3

Patient Cohort and Sample Details

To investigate the effect of augmenting digital pathology images
with RCI, a study was conducted on a cohort of 32 prostate cancer
patients. 178 TMA samples were obtained as multiple samples
could be extracted from a single patient’s radical prostatectomy
tissue. 66 Cancer TMA samples were pathologically confirmed normal, Gleason grade 3 or 4, as according to the paper by Breen et
al. 66 Raman chemical images of the samples were acquired with
the pathologically verified label being transferred from the digital
pathology sample to its Raman counterpart. Table 1 outlines the
data summary and class distribution of non-cancer, Gleason grade
3 and grade 4 samples.
J
our
na
l
Na
me,
[
y
ea
r
]
,
[
vol
.
]
,
1–19 | 3

Table 1 Class balance details for 32-patient cohort

Class
Non-cancer
Cancer
Total
Cancer
Breakdown
Gleason 3
Gleason 4
Gleason 5
Total

82
97
179

No. of
Raman
Chemical
Images
82
97
179

51
45
1
97

51
45
1
97

No. of Digital
Pathology
Images

% of Total
Samples
45.8%
54.2%
100.0%

ing, histogram equalization was applied to each greyscale Raman
image. This transform flattens the greyscale image histogram in
an effort to ensure that all intensity values are equally distributed.
It is a common technique for normalizing image intensity prior to
further processing. Figure 2 shows the image intensity histogram
of a greyscale Raman chemical image before and after histogram
equalization.

52.6%
46.3%
1.0%
100.0%

2.4 Image pre-processing
Pretreatment of Raman spectra included the removal of saturated
pixels followed by cosmic ray correction using in-house functions
in MATLAB 2019a. Spectra were used to form Raman chemical
images with each spectrum constituting a single pixel of a tissue
sample image. Each TMA sample’s Raman chemical image was
approximately 33 x 33 pixels. The mean of each pixel’s spectrum
was used to form a grey scale 2-D Raman chemical image. The
Raman chemical images were then upsampled to 500 x 500 pixels
using cubic spline interpolation. Up-sampling better facilitated
the discovery of useful local and global features before input to
the SIFT feature detection algorithm.
Colour optical microscopy (digital pathology) images (approximately 1500 x 1500 pixels) were converted to greyscale via
the Python OpenCV package which implements the conversion
function:
Y = 0.299*R + 0.587*G + 0.114*B
where R, G and B represent the red, green and blue channel intensity values. The greyscale digital pathology images were
then downsampled to match the resolution of the corresponding
500 x 500 Raman images.

Fig. 2 Image intensity histograms of greyscale Raman chemical image
before (left) and after (right) application of histogram equalization.

2.5

Two binary classification tasks (non-cancer/cancer and Gleason
grade 3/grade 4) were investigated for three imaging configurations. The first configuration was digital histopathology (optical
microscopy), the second utilised RCI and the third was a combination of digital histopathology and RCI. Five-fold cross validation with each fold containing samples from disjoint sets of patients was investigated i.e patient sample independence was ensured. The feature extraction approach used in this study first
partitions images into reference and classification sets. Reference images were used to form image features which then encode the classification set. 179 images were used for the binary
non-cancer/cancer task - 52 reference images for defining the image features and 127 for building the classification models. 96
images were used for the Gleason grade 3/grade 4 task – 27 reference images and 69 images for the classification models. Both
binary classification tasks were evaluated using a single reference
and classification partition. On witnessing promising results for
the task of Gleason grade 3/ grade 4 differentiation, modelling
was extended to incorporate 10 different reference/classification
partitions (average performance metrics over the 10 models were
reported). This amounted to 9 model configurations in total. Table S3 in the Supplementary Material gives an overview of the
models investigated.
2.6

Fig. 1 Two Gleason grade 4 samples ((a) and (b)) and a non-cancer
sample (c). Colour digital histopathology images are shown in (a) to (c)
with corresponding Raman images in (d) to (f).

Visually, the upsampled greyscale Raman chemical images have
low contrast values i.e. most of the pixel intensity values exist in a
relatively narrow range per image. As a means of contrast stretch-
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Image-based model configurations

Models with Single & Multiple Reference Sets

SIFT feature encoding of the classification sets for models 1-6 in
Table S3 were based on a single reference set. Reference sets
were formed from samples belonging to a randomly selected set
of patients. These patients and their samples were not used in
the classification sets. The reference set of images were used to
encode the remaining images (using the technique explained in
the Feature Extraction section). These remaining images consti-

tuted the classification set and were used for model training and
evaluation via cross-validation. Cross-validation was structured
such that samples from 5 disjoint sets of patients were used in
each fold - this ensured patient independence across folds.
For models 7-9 in Table S3, 10 separate models based on differing reference/classification partitions were generated. Mean
cross-validation performance scores were generated for each of
the 10 models with the overall average of these individual means
reported. As described above, the same approach to patient independence across the reference sets and cross-validation folds was
followed.
2.7

Reference - Classification Sets and Dictionary Sizes

The aforementioned reference sets were used to form dictionaries
of visual words for each model. Table 2 shows the breakdown of
images used for both the reference and classification sets for each
diagnostic classifier and pathological class (single reference set
case).

points of interest from grey-level images. Statistics relating to
local gradient directions of image intensities are collected which
give a description of local image structures in an interest point’s
local neighbourhood. 69 Figure 3 outlines the SIFT detection and
description process. The results of Scale Invariant Feature Transform yield high-dimensional feature vectors, each describing a
single key point. Exhaustive matching of key point descriptors
across images can be avoided by utilizing the classic bag-of-words
paradigm from the field of information retrieval. 70 The key point
descriptors extracted by the SIFT algorithm are grouped into clusters with each cluster containing similar descriptors. Each cluster
can be treated as a visual word that represents certain local patterns which are common among the descriptors in that cluster.
The combination of these clusters yields a visual word vocabulary that describes a range of local image patterns. This mapping
of key points to visual words represents a dictionary that can be
used to represent the image as a bag of visual words.

Table 2 Reference and Classification Set Image Distribution
Set
Reference

Diagnostic
Model
Non-cancer/
Cancer

Gleason 3/4
Non-cancer/
Classification
Cancer
Gleason 3/4

Normal G3

G4

G5

Total

23

16

12

1

52

12

15

27

35

33

127

39

30

69

59

The dictionary size parameter was optimized in a similar fashion to the optimisation of the support vector machine (SVM)
hyperparameters. For the single imaging approach of digital
histopathology, image histograms were generated and passed to
the classification stage over a range of investigated dictionary
sizes. These were [50, 75, 100, 200, 300, 500, 1000], which
represent the number of visual words that were generated via the
BoVW clustering stage and thus the visual words used to encode
an image as a histogram of visual word frequencies. In the case of
the RCI single imaging approach, the dictionary sizes used were
[5, 10, 25, 50, 100, 200, 300]. For the multimodal approach,
the range of dictionaries investigated were combinations of the
values used for both single imaging approaches i.e. [50, 75, 100,
200, 300, 500, 1000] and [5, 10, 25, 50, 100, 200, 300] for the
digital pathology and RCI images respectively. Image histograms
of visual words were generated for each value in the tested ranges
with permutations of these being used to optimise each model.
2.8

Feature Extraction

Scale Invariant Feature Transform (SIFT) was used to extract image features. SIFT is an image descriptor that can be used for image recognition. The descriptor shows invariance to scaling, rotation and translation in the image domain and exhibits robustness
to moderate illumination variation and perspective transforms.
The SIFT descriptor has been shown to be effective in practice
for real-world object recognition. It utilizes a method that detects

Fig. 3 The SIFT detection and description process. (a) the difference
of Gaussians is computed at multiple scales. X is a potential keypoint
that is compared to its 8 neighbours at the same scale and 9 corresponding neighbouring pixels at each neighbouring scale ; (b) A scale
is selected for each keypoint; (c) The Gaussian smoothed image at the
keypoint’s scale is used to assign orientation. Gradient orientations are
computed at that scale. The large circle represents the weighting of a
Gaussian window when the orientation histograms are being calculated;
(d) The orientations are spatially pooled; (e) This yields histograms that
are concatenated and normalised to form the descriptor. Figure adopted
from 71 .

This equates to a vector containing the visual word count which
can then be used at the classification stage. 72 In the case of the
combined digital pathology and Raman imaging models, the feature vectors extracted from each modality were concatenated to
form a single representation of the image pair for a tissue microarray sample. For the single modality cases, just the feature
vector derived from the digital pathology or Raman chemical image was utilized. Figure 4 shows the main stages of the Bag of
Visual Words approach.
The main steps outlined in Figure 4 involve:
(a) The reference images are decomposed into many SIFT features. By K-Means clustering, these SIFT features are clustered
to a predefined number of clusters. The centroids of these clusters are referred to as visual words. In this example, three visual
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Fig. 4 A diagram illustrating how to generate the bag-of-words visual words from several Raman Chemical Imaging reference images and how to
represent an image by a bag-of-words histogram associated with these visual words. Figure adapted from 73 .

words are generated. The set containing all the visual words is
referred to as a dictionary e.g. 27 reference images were used to
build a visual word dictionary for the Gleason grade 3/ grade 4
classification model.
(b) Given a new image to be represented by a bag-of-words
model, it is first decomposed into several SIFT features. Each SIFT
feature is assigned to the nearest visual word using Euclidean distance i.e. vector quantization. Implementing such feature assignment for each SIFT feature, the image can be represented as a
histogram of visual word frequencies i.e. the counts of the occurrences of the SIFT features assigned to each visual word. 73
For the Gleason grade 3/4 classifier, 69 images were converted
to visual word histograms based on the dictionary formed by the
27 reference images. These 69 images were then used to build
a cross-validated classification model. The same process was applied for histopathology images.

2.9

Image Histogram Visualisation

The process of SIFT feature extraction and BoVW clustering yields
image representations in the form of histograms of visual words.
These frequency distributions detail how many of each type of
feature (visual word) occurs in a given image. Fig. 5 shows examples of normal and cancer tissue sample BoVW image histograms
for H&E and Raman chemical imaging. Similarly, for the cases of
Gleason grade 3 and 4, Fig. 6 contains examples of tissue sample
BoVW image histograms pertaining to both image modalities.
6|
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Fig. 5 BoVW image histograms for a normal tissue sample H&E image
(top left) with corresponding RCI image (top right) and a cancer tissue
sample H&E image (bottom left) with corresponding RCI image (bottom
right).

2.10

Image Feature Representations for Classification

The histogram image representations generated in the feature extraction step are then passed to a classification algorithm. In the
case of the combined digital pathology/RCI models, the feature
vectors extracted from each modality were concatenated to form
a single representation of the image pair for a tissue microarray
sample. With the images converted to vector representations (histograms), a support vector machine was utilized to learn from
training images and classify test images. Based on these image

Fig. 6 BoVW image histograms for a Gleason grade 3 tissue sample H&E
image (top left) with corresponding RCI image (top right) and a Gleason
grade 4 tissue sample H&E image (bottom left) with corresponding RCI
image (bottom right).

representations, the classifier outputs probability-like values that
a tissue sample belongs to a given class.
Five-fold cross validation was used to assess the efficacy of
models. This is a robust approach which partitions images into
5 approximately equal sized folds. Given that there were multiple sample images per patient, the folds of the cross-validation
were formed from 5 disjoint sets of patient sample images. This
approach ensures the independence of the training and test data
sets within the cross-validation process. The overall algorithmic
process is outlined in Figure 7.
2.11 Classification with Support Vector Machines
For the application of the SVM, the software package sklearn.svm
from Python was used (version sklearn==0.0). 75 This involved
implementation of the SVC (support vector classification) class
which is based on libsvm. Two kinds of kernel functions were
compared i.e. linear and radial basis function (RBF) in each experiment. Parameters were optimised by searching the four/fivedimensional grid which is created by ranges of C, γ, the chosen kernel and the SIFT/BoVW dictionary sizes for each imaging
modality.
The permutation of these parameters which returns the maximum accuracy determines the optimal model. C is a penalty parameter for misclassification while γ is related to the radius of
influence of the support vectors that the model selects. The grid
search process for parameter optimisation involved several steps:
1. Parameter C was sampled over the range [2-5 , 2-4 ,...,215 ]
while γ was sampled over the range [2-15 , 2-14 ,...,23 ]. 76 The kernels tested were linear and radial basis function. Other model
parameters used the default settings of the package.
2. The parameters given by the dictionary sizes for digital
pathology and RCI were sampled over [50, 75, 100, 200, 300,
500, 1000] and [5, 10, 25, 50, 100, 200, 300] respectively. This
equated to images being represented by histograms of varying
length, equivalent to the number of visual words created via the
clustering process of the BoVW dictionary generation.
3. Given the five parameters used for optimisation in the multimodal imaging approach i.e. digital pathology and RCI, the num-

ber of permutations searched is given by the product of the length
of each parameter vector. In the case of the single modality model
i.e. digital pathology imaging or RCI only, total permutations are
given by the product of the length of four parameter value vectors i.e. C, γ, kernel choice and dictionary size. The process of
parameter optimisation is discontinuous and attempts to find the
global minimum for model error and maximum for model accuracy. It is unlikely that a true global minimum/maximum could
be found given that a continuous search over unbounded ranges
of the parameters is practically impossible. Additionally, a continuous differentiable function whose derivative exists at each point
in the domain and that can be analytically solved is unknown.
4. Each parameter combination was used to derive image histograms of specified size and set SVM parameter values. Five-fold
cross validation was used to assess the performance of the model
with the metrics sensitivity, specificity, overall accuracy, AUC and
the ROC curve being used to interpret results. Accuracy was optimised with the classes for each model being well balanced. Metrics from the cross-validation process were calculated as the mean
values over each of the five folds. The probability-like values and
categorical predictions obtained from the SVM classifier over each
fold were used to form an ROC curve and confusion matrix for the
entire dataset. Tables S4 and S5 outline the parameters of the optimised SIFT/BoVW SVM models.
2.12

Classification using Raman spectral data

For comparison with the image-based approaches, classification
models were also constructed using median Raman spectra per
sample, as described below.
2.13

Calculation of median Raman spectrum

For each Raman image collected, several pre-processing steps
were carried out prior to calculation of the median Raman spectrum for each sample. First, in order to remove the image background (i.e. non-sample parts of the image), principal components analysis was applied to each image individually. The principal component (PC) score images were visually assessed, and
the score image that best separated the sample from the background was selected. A mask was then created by thresholding
that PC score image based on the distribution of pixel intensities
in the PC score image histogram. Pixels containing cosmic rays
and saturated spectral regions were subsequently removed using
the approach described by Dorrepaal et al. 77
Briefly, for each spectrum, standard normal variate pretreatment was applied to the spectrum; the difference in intensity between neighboring Raman shifts was calculated and the standard
deviation of this ‘difference’ spectrum was calculated. Spectra
with a standard deviation greater than the mean +/- 3 times the
standard deviation of this value were identified as Cosmic Rays or
saturated pixels and removed from the image by masking. Finally,
in some image masks, very small regions outside of the core were
noticed (possibly due to fragmentation of a core or residue from
processing). In order to remove these from the images, all image
regions with less than 10 pixels were identified and set to zero
in the mask. A composite mask ( = background removal + cosJ
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Fig. 7 Algorithmic process for feature extraction and classification for single and multimodal imaging cases. (a) Feature extraction (SIFT descriptors),
(b) K-Means clustering yields visual words, (c) Feature quantization to create visual word histograms per image, (d) Classification stage. Figure
adapted from 74 .
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mic ray/saturated pixels + small regions masks) was created and
applied to the image. Subsequently the median Raman spectrum
was calculated for each image.
2.14

PLS-DA modelling

Partial least squares discriminant analysis was applied to the median Raman spectra of the unstained TMAs for comparison with
the multi-modal imaging approach. Models were constructed
using untreated Raman spectra and six spectral pretreatments:
SNV, 1st derivative Savitzky Golay pretreatment (‘1st der’, window size = 15 points, polynomial order = 3), 2nd derivative Savitzky Golay pretreatment ((‘2nd der’, window size = 15 points,
polynomial order = 3), combinations of SNV followed by 1st or
2nd derivative pretreatment and multiplicative scatter correction
(MSC). In addition, the fluorescence background was removed
from the spectra using an exaggerated smoothing (0 order Savitzky Golay smoothing with a window size of 301) and subtracting the smoothed spectrum from the original median Raman spectrum. This pretreatment was then followed by the 6 spectral
pretreatments described above. Model parameters such as optimal pre-treatment and number of latent variables were selected
by random cross validation on the data from the SIFT sets for
non-cancer/cancer discrimination and Gleason grade 3/grade 4
discrimination. For random cross validation, 70% of the spectra were randomly selected for model building and the remaining
30% were used for cross validation (the ‘randperm’ function in
MATLAB was used to randomly permute the data). This process
was repeated 200 times and the mean accuracy, sensitivity and
specificity were calculated for each combination of spectral pretreatment and number of latent variables. The optimal spectral
pretreatment and number of latent variables was selected based
on consideration of the mean accuracy, and product of sensitivity and specificity. Subsequently, 5-fold cross validation using the
selected parameters was carried out using the same folds as used
in the image based models. As described in Section 2.10, the
cross-validation was structured such that samples from 5 disjoint
sets of patients were used in each fold - this ensured patient independence across folds. Using the selected model parameters,
calibration models were then re-built on the combination of the
SIFT reference sets and the calibration set for a given fold number, and validated on the corresponding independent patient set.
Unless otherwise specified, Raman image processing was carried
out using MATLAB (MATLAB R2019a, The MathWorks Ltd) functions written in house and from the image processing toolbox.

3

Results

This study compared the performance of single modality approaches (digital histopathology, Raman chemical imaging (RCI)
and median Raman spectra) to a multimodal (RCI + digital pathology) approach in classifying the pathological state of
prostate tissue samples using SIFT and a support vector machine
(SVM) classifier. A random set of patient’s samples were used as
the reference image set. Features from this set were clustered to
yield visual words, which were then used to encode images in the
classification set. Two binary classification tasks were explored in

order to show the competing performance of the single and multimodal imaging approaches. These tasks were cancer/non-cancer
and Gleason grade 3/grade 4 binary classification. Each of these
tasks were tested with regard to both the single and multimodal
imaging input types. The classification algorithm makes a diagnostic prediction based on the extracted features for each TMA
core sample.
3.1

Classification using Raman spectra

Classification results for cancer vs. non-cancer based on PLS-DA
models constructed on median Raman spectra are presented in
the Supplementary material. The optimal PLS-DA model parameters (based on maximum product of sensitivity and specificity)
were selected as no pretreatment followed by 2nd derivative Savitzky Golay pre-processing and a PLS-DA model with 9 latent variables. PLS-DA models using these parameters were then built and
cross validated on the 5 folds used in the imaging models.
The resultant confusion matrix is shown in Figure 8. The accuracy of this approach was 58.3%, with a sensitivity of 0.62 and a
specificity of 0.54.

Fig. 8 Confusion matrix for classification of cancer vs. non-cancer samples using Raman spectra (left) with confusion ball graphic of specificity
and sensitivity (right). Confusion matrix based on pooled predictions
over 5-fold cross-validation. Sensitivity and specificity are mean values
over cross-validation folds.

As for the PLS-DA models for Gleason grade 3/grade 4 classification, the product of mean sensitivity and specificity calculated
over 200 random splits of the reference image set (shown in Figure S2) indicated optimal PLS-DA model parameters to be fluorescence removal followed by 1st derivative preprocessing and
a PLS-DA model with 4 latent variables. PLS-DA models using
these parameters were then built and cross validated on the same
5 folds used for the imaging models. The resultant confusion matrix is shown in Table S2. The accuracy of this approach was 42%,
with a sensitivity of 0.33 and a specificity of 0.49.
These results show that the use of median Raman spectra alone
produces relatively poor classification models, suggesting the
need to consider the image related features in subsequent modelling. Therefore, in addition to a representative median spectra
approach, we investigated a method based on the greyscale Raman chemical image of the tissue sample, calculated using the
mean spectral value per pixel. This approach allowed the incorporation of both biochemical data from pixel spectra and structural and morphological information via the spatial distribution
of pixel intensities.
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3.2

Classification using Raman Chemical Imaging

Using RCI images, a 5-fold cross-validated model was constructed
based on images encoded by a random reference set as detailed in
Section 2.8 and Table 2. The binary non-cancer/cancer classifier
yielded a sensitivity and specificity of 72.5% ± 0.1% and 69.0%
± 0.1% respectively (Figure 9) with a reported accuracy of 70.3%
± 2.8% and AUC of 0.707 ± 0.038.
Fig. 11 Confusion matrix for classification of cancer vs. non-cancer
samples using digital pathology imaging alone (left) with confusion ball
graphic of specificity and sensitivity (right). Confusion matrix based on
pooled predictions over 5-fold cross-validation. Sensitivity and specificity
are mean values over cross-validation folds.

Fig. 9 Confusion matrix for classification of cancer vs. non-cancer
samples using RCI imaging alone (left) with confusion ball graphic of
specificity and sensitivity (right). Confusion matrix based on pooled predictions over 5-fold cross-validation. Sensitivity and specificity are mean
values over cross-validation folds.

Gleason grade 3 and 4 classification was then investigated using RCI imaging. Similarly, a 5-fold cross-validated model with
images encoded by a random reference set was investigated. The
model achieved an accuracy of 68.0% ± 20.0%, sensitivity of
72.7% ± 22.5% and specificity of 68.0% ± 29.5% (Figure 10).
The AUC was found to be 0.750 ± 0.192. Results in this section
were mean values per fold.

Fig. 10 Confusion matrix for classification of Gleason grades 3 and
4 samples using RCI imaging alone (left) with confusion ball graphic
of specificity and sensitivity (right). Confusion matrix based on pooled
predictions over 5-fold cross-validation. Sensitivity and specificity are
mean values over cross-validation folds.

The binary classification of Gleason grade 3 and 4 was investigated using only features from digital pathology images. Applying
a 5-fold cross-validated model with images encoded by a random
reference set, an accuracy of 74.1% ± 9.3%, sensitivity of 54.1%
± 30.0% and specificity of 84.7% ± 3.0% was achieved (Figure
12). AUC was given as 0.731 ± 0.211. Results in this section
were mean values per fold.

Fig. 12 Confusion matrix for classification of Gleason grades 3 and 4
samples using digital pathology imaging alone (left) with confusion ball
graphic of specificity and sensitivity (right). Confusion matrix based on
pooled predictions over 5-fold cross-validation. Sensitivity and specificity
are mean values over cross-validation folds.

3.4
3.3

Classification using Multimodal Imaging

Classification using Digital Pathology Imaging

Using digital pathology images, a 5-fold cross-validated model
was constructed based on images encoded by a random reference
set. The binary classification of cancer and non-cancer samples
yielded a sensitivity and specificity of 81.9% ± 15.3% and 80.0%
± 16.4% respectively (Figure 11) with a reported accuracy of
82.3% ± 6.0% and AUC of 0.878 ± 0.058.
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The multimodal model of digital pathology and Raman imaging
applied to classification of non-cancer/cancer samples yielded a
sensitivity and specificity of 78.4% ± 18.7% and 81.6% ± 6.9%
respectively on 5-fold cross-validation with a random reference
set for encoding classification images (Figure 13). Accuracy was
found to be 80.8% ± 7.7% with AUC being 0.845 ± 0.065.

Fig. 13 Confusion matrix for classification of cancer vs. non-cancer
samples using combined digital pathology and Raman imaging (left) with
confusion ball graphic of specificity and sensitivity (right). Confusion matrix based on pooled predictions over 5-fold cross-validation. Sensitivity
& specificity are mean values over cross-validation folds.

In the case of Gleason grade 3 and 4 classification, a model
utilising features from both digital pathology and Raman imaging
modalities gave an accuracy, sensitivity and specificity of 82.8%
± 18.1%, 73.8% ± 27.3% and 88.1% ± 16.8% respectively for 5fold cross-validation, with images encoded by a random reference
set (Figure 14). The AUC was 0.858 ± 0.186. Results in this
section were mean values per fold.

Fig. 15 Receiver operator characteristic (ROC) comparison of binary
cancer/non-cancer classifiers for digital pathology, Raman chemical imaging and the multimodal combination of both imaging types. Curves and
AUC values are based on pooled model predictions from 5-fold crossvalidation.

For the classification of Gleason grade 3 and 4 samples, ROC
curves for digital pathology, Raman chemical imaging and the
multimodal combination of both are shown in Figure 16. The improvement in diagnostic ability when augmenting digital pathology with RCI is evident. The AUC values in both ROC graphs are
generated from the pooled predictions over the 5 cross-validation
folds which accounts for the difference when compared with the
mean AUC values per fold.

Fig. 14 Confusion matrix for classification of Gleason grades 3 and 4
samples using combined digital pathology and Raman imaging (left) with
confusion ball graphic of specificity and sensitivity (right). Confusion matrix based on pooled predictions over 5-fold cross-validation. Sensitivity
& specificity are mean values over cross-validation folds.

3.5

ROC Curves Comparison

For the binary classification of cancer and non-cancer samples,
the ROC curves for Raman chemical imaging, digital pathology
and the multimodal combination of both imaging modalities can
be seen in Figure 15. The receiver operator characteristic (ROC)
curves indicate that models based on the single modality of digital pathology and multimodal combination of digital pathology
and Raman chemical imaging exhibit closely matched diagnostic
ability.
From observation of the ROC curve in Figure 15, it can be seen
that the digital pathology model (red curve) generally achieves
slightly better sensitivity than the multimodal model with the exception of the region where specificity ranges between 80% and
90%. RCI does exhibit some ability to differentiate sample classes
but appears to add little when combined with the digital pathology approach for the non-cancer/cancer task.

Fig. 16 Receiver operator characteristic (ROC) comparison of Gleason
grade 3 and 4 classifiers for digital pathology, Raman chemical imaging
and the multimodal combination of both imaging types.Curves and AUC
values are based on pooled model predictions from 5-fold cross-validation.

3.6

Multiple Reference Set Results and T-test

Paired t-tests were conducted to ascertain if there was a significant difference in the AUC values of the digital pathology and
multimodal models presented in the preceding sections. The AUC
values were those calculated on the validation sets of the 5-fold
cross-validation of both models. No significant difference was observed between the digital pathology and multimodal approaches
for the binary non-cancer/cancer classification task. The mean
AUC difference (M=0.033, SD=0.064, N=5) was not significantly greater than zero, t(5)=2.776, two tail p=0.318. However,
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in the case of Gleason grade 3/grade 4 classification, the fusion
of digital pathology and RCI showed potential for improved diagnostic performance for prostate cancer severity. The mean AUC
difference (M=0.127, SD=0.059, N=5) was significantly greater
than zero, t(5)=2.776, two tail p=0.009, providing evidence that
the model is effective in improving binary classification of Gleason grade 3 and 4 prostate cancer. The 95% confidence interval
about the mean difference is (0.054, 0.201).
Results pertaining to the Gleason grade 3/grade 4 classification task where the average performances were reported over ten
models (each model with different random patient groupings for
the reference set and cross-validation folds) are contained in Table 3.
Table 3 Average results of 5-fold cross-validation over 10 models (randomly selected patient groups for reference set and cross-validation folds)
for Gleason grade 3/4 classification across digital pathology (DP), Raman
Chemical Imaging (RCI) and multimodal approaches (DP + RCI)

Imaging
Modality

Sensitivity Specificity AUC

RCI
DP
Multimodal

63.3%
63.5%
74.9%

77.8%
84.9%
83.4%

0.714
0.764
0.826

False
Negative
Rate
36.7%
36.5%
25.1%

It was noted that there was generally a reduced advantage between the multimodal and digital pathology model for Gleason
grade 3 and 4 classification when taking the average results of 10
different configurations of reference set and cross-validation folds
(Table 3), as compared to results using a single reference set in
Sections 3.3 and 3.4.

4

Discussion

Integration of Raman spectroscopy with other modalities can
lead to significantly improved performance of a combined multimodal measurement in comparison to what either modality could
achieve alone. 78 Raman spectroscopy and its derivations are valuable for a range of clinical applications in the field of medicine
including prostate cancer. 28 To date, few studies have investigated the value in combining Raman Chemical Imaging (RCI)
with other modalities. This work explores the integration of digital histopathology with RCI for the classification of prostate cancer tissue samples. We investigated whether a machine learning
algorithm could perform better using this multimodal approach
in comparison to utilising a range of single imaging inputs. Sample labels defined from pathologist examination of H&E images
were applied to the corresponding RCI images.
The developed machine learning algorithm predicts the pathological grade of the sample based on extracted image features.
Two binary classification models were developed: the first classifies tissue samples as cancer or non-cancer with the second differentiating malignant samples as Gleason grade 3 or 4. The study
compared performances of models utilizing the single modalities
of digital histopathology, RCI and median Raman spectra in addition to the multimodal combination of digital histopathology
and RCI. It was observed that the multimodal imaging approach
outperformed single imaging for the differentiation of Gleason
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grades 3 and 4. The best binary non-cancer/cancer models were
those utilising digital pathology images and multimodal digital
pathology/RCI images, with both achieving similar performance.
Given that binary non-cancer/cancer diagnosis is a simpler task
than differentiation of Gleason grade 3 and 4, there may have
been enough information in the histopathological sample images
to preclude any advantage from multimodal imaging. However,
as pathologists can find it more challenging to differentiate between Gleason grade 3 and 4, the additional sub-visual information from the unstained RCI images may explain the improved
diagnostic performance observed in this case.
Differentiation of Gleason grades 3 and 4 is a clinically relevant problem with a potentially high cost of error in assessment
of these patterns. Where the discovery of a Gleason pattern 4 on
follow-up biopsy would prompt the termination of active surveillance for a patient, misclassification of Gleason patterns 3 and 4
would have a major therapeutic impact. 79 In the case of Gleason grade 3 and 4 classification, a paired t-test indicated that the
mean difference in area under the ROC curve for cross-validation
fold values was significantly greater than zero where P<0.05 was
considered statistically significant. This observation implies that
there are properties and features of the RCI image that augment
the information derived from histopathological images. This may
be a reasonable assumption given that RCI produces a biochemical map of the sample with the intensities of the mean Raman
image deriving directly from the spectral contributions of various
biological components such as DNA, RNA and the extracellular
matrix. Additionally, the spatial property of RCI contributes morphological information by accounting for changes in intensities
within local neighbourhoods and thus identifying structural features within the sample.
A further finding of note is the relatively good performance of
the Gleason grade 3/4 classification model that used RCI imaging
only as input. This suggests potential to use mean Raman images
for Gleason grade 3/4 diagnosis. Less processing (such as chemical staining of samples) would be required with a few spectral
points needed to form the chemical image. A lower cost/relatively
rapid Raman-based device could potentially be constructed using
this principle.
In this study, limited samples precluded the use of a separate
test set in addition to the cross-validation approach used. The
classification algorithms would benefit from acquisition of more
data with the increased training likely leading to greater robustness and improved predictive power. The study is a preliminary
validation; to improve chances of developing a clinically useful diagnostic classifier, the proposed multimodal imaging model
should be trained on samples from a significant cohort of patients
and evaluated on data from a range of hospitals and laboratories. This would introduce greater variation and better reflect
real world data that the diagnostic classifier would encounter.
The primary stages of the model were image preprocessing, feature extraction and classification. Histogram equalization, SIFT
with visual BoW and an SVM classifier were utilized to propose a
model that could serve in diagnosis of prostate cancer pathological grades within a digital histopathological and Raman chemical imaging workflow. Support vector machines are commonly

used due to their computational efficiency and robustness as they
minimize over-fitting by adding structural constraints. Despite
these properties and the use of stratified K-fold cross validation,
additional validation on larger datasets and the use of separate
test sets are required to further assess the generalizability of our
models. Other limitations of the study include the use of multiple
samples per patient. To ensure patient independence in the modelling process, samples from disjoint sets of patients were used for
the reference and cross-validation folds. In our study, labelling is
done by a single pathologist, which may carry greater misclassification risk versus having multiple labelers. The employment
of a consensus pathology approach should strengthen the ground
truth.
With acquisition of extended data, future work would include
the application of deep learning and transfer learning to assess
RCI augmentation of digital pathology and the use of methods
that facilitate some degree of explainable artificial intelligence so
that the model diagnostic decision process could be interrogated.
The addition of a tumour segmentation step is worth exploring as
many studies benefit from guiding the feature extraction process
to specific areas of the image.

5

Conclusion

Multimodal image analysis is an important area of biomedical
science. The combination of information from multiple sources
can lead to improved diagnosis and treatment strategies, directly
benefiting the patient’s quality of life and prognosis. This work
demonstrates that the fusion of digital histopathology and Raman
chemical imaging modalities has potential to improve the diagnostic performance for prostate cancer by integrating both morphological and biochemical information across both data sources.
Comparative results across the single and multimodal approaches
to non-cancer/cancer and Gleason grade 3/grade 4 differentiation indicates that a multimodal approach does not improve tumour identification but is useful for the more challenging task of
tumour severity identification.
The reasonable performance of approaches based on Raman
chemical imaging only, indicates potential for a cost-effective and
rapid means of assessing prostate cancer grades without requiring staining. However, while this study suggests that the integration of digital histopathology and Raman chemical imaging is a
promising research method for the critical and challenging diagnosis of Gleason grade 3 and 4, the observed modest improvement should be considered in the context of the current cost and
time required for Raman chemical imaging.
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Supplementary Figures

Fig. S17 Product of sensitivity and specificity for PLS-DA models constructed on median Raman spectra for non-cancer/cancer classification. Values
shown are the mean calculated over 200 random splits of the reference image set. Models were constructed using untreated Raman spectra and six
spectral pretreatments: standard normal variate pre-processing (SNV), 1st derivative Savitzky Golay pretreatment (‘1st der’, window size = 15 points,
polynomial order = 3), 2nd derivative Savitzky Golay pretreatment ((‘2nd der’, window size = 15 points, polynomial order = 3), combinations of SNV
followed by 1st or 2nd derivative pretreatment and multiplicative scatter correction (MSC). The optimal PLS-DA model parameters were selected as
no pretreatment followed by 2nd derivative preprocessing and a PLS-DA model with 9 latent variables. * 9 LV SG2 model
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Fig. S18 Product of sensitivity and specificity for PLS-DA models constructed on median Raman spectra for Gleason grade 3/ Gleason grade 4.
Values shown are the mean calculated over 200 random splits of the reference image set. Models were constructed using untreated Raman spectra
and six spectral pretreatments: standard normal variate pre-processing (SNV), 1st derivative Savitzky Golay pretreatment (‘1st der’, window size = 15
points, polynomial order = 3), 2nd derivative Savitzky Golay pretreatment ((‘2nd der’, window size = 15 points, polynomial order = 3), combinations
of SNV followed by 1st or 2nd derivative pretreatment and multiplicative scatter correction (MSC). The optimal PLS-DA model parameters were
selected as fluorescence removal followed by 1st derivative preprocessing and a PLS-DA model with 4 latent variables.
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Supplementary Tables
Table S4 Confusion matrix for 9 latent variable PLS-DA model constructed on median Raman spectra (no pretreatment followed by 2nd derivative
preprocessing) for Non-Cancer (NC) /Cancer (C) classification using 5 fold cross validation

Actual NC
Actual C

Predicted NC
32
27

Predicted C
26
42

Table S5 Confusion matrix for 4 latent variable PLS-DA models constructed on median Raman spectra (pretreated by fluorescence removal followed
by 1st derivative preprocessing) for Gleason Grade 3/ Gleason Grade 4 (G3/G4) classification using 5 fold cross validation

Actual G3
Actual G4

Predicted G3
19
20

Predicted G4
20
10

Table S6 Details of non-cancer/cancer (NC/C) and Gleason grade 3/grade 4 (G3/G4) models including diagnosis, modalities and number of reference
sets. 5-fold cross-validation was used, which incorporated samples from disjoint groups of patients.
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Model No.

Diagnosis

1
2
3
4
5
6
7
8
9

NC/C
G3/G4

Imaging
Modality
DP
RCI
DP+RCI
DP
RCI
DP+RCI
DP
RCI
DP+RCI

No. of
Reference Sets
1
1
1
1
1
1
10
10
10

Table S7 Parameters pertaining to optimal SIFT/BoVW/SVM classifiers that used samples from a single randomly selected set of patients as a
reference set. Diagnostic tasks are non-cancer/cancer (NC/C) and Gleason grade 3/grade 4 (G3/G4) with digital pathology (DP), Raman Chemical
Imaging (RCI) and multimodal (DP+RCI) imaging modalities
Diagnosis
NC/C

G3/G4

Imaging Modality
DP
RCI
DP+RCI
DP
RCI
DP+RCI

Dictionary Size 1
300

Dictionary Size 2
50
10

300
200

5
5

300

C
211
28
212
27
213
28

γ
20
2
2−1
23
23
22

Kernel
rbf
rbf
rbf
rbf
rbf
rbf

Table S8 Parameters pertaining to optimal SIFT/BoVW/SVM classifiers. Each imaging modality was investigated using results from 10 different
models, each using different sets of samples for reference images. The diagnostic task is Gleason grade 3/grade 4 (G3/G4) differentiation with digital
pathology (DP), Raman Chemical Imaging (RCI) and multimodal (DP+RCI) imaging modalities
Imaging Modality
DP

RCI

DP+RCI

Reference Set No.
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10

Dictionary Size 1
100
500
500
1000
50
500
100
200
1000
500

50
200
100
1000
50
200
50
300
1000
75

Dictionary Size 2

10
25
5
10
5
100
25
5
25
25
5
50
5
10
5
5
50
5
5
5

C
212
28
29
27
214
29
212
27
211
29
24
29
22
215
25
28
22
213
26
26
214
28
28
212
212
211
28
28
29
214

γ
20
21
22
23
2−1
21
20
23
21
23
2−1
22
2−1
2−1
22
22
23
21
21
2−1
21
21
2−2
2−2
2−1
21
22
22
2−3

Kernel
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
linear
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
rbf
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